# A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

> **NCT04839926** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Nhwa Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** 0.5mg CY150112
- **DRUG:** 1.5mg CY150112
- **DRUG:** 4.5mg CY150112
- **DRUG:** 10mg CY150112
- **DRUG:** 18mg CY150112
- **DRUG:** 24mg CY150112

## Key facts

- **NCT ID:** NCT04839926
- **Lead sponsor:** Jiangsu Nhwa Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-02
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04839926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04839926, "A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04839926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*